During his presentation, Martien Kas, Professor of Behavioral Neuroscience of the Groningen Institute for Evolutionary Life Sciences at the University of Groningen in the Netherlands, discussed how digital tools such as smartphones, smartwatches, and other wearable healthcare devices are capable of not only measuring patients’ physical movements, but also capturing data on their mental health and general well-being.
The schizophrenia polypharmacy quiz – everything you need to know about combining antipsychotics’ was an interactive session at the 34th ECNP Congress. Professor Stephan Hjorth and his co-speaker Dr. Karolina Leopold addressed the efficacy and safety concerns of different antipsychotic combinations from a pharmacological and clinical point of view
During the ‘From symptom control to long-term functioning – bridging treatment adherence to functional recovery in schizophrenia’ symposium, four expert speakers looked at the importance of linking acute and long-term treatment objectives in early schizophrenia. In particular, the case for giving a medication that patients will be certain to take was emphasized, with speakers making the case for using long-acting injectable (LAI) antipsychotic drugs earlier in the course of the illness.
THINKING CLEARLY WITH SCHIZOPHRENIA – IS COGNITIVE IMPAIRMENT THE OBSTACLE HOLDING YOUR PATIENT BACK?
Professors Peter Falkai, Dr. Berlet, Dr. Nagore Penades, Professor and Philip D. Harvey outlined the reality of living with cognitive impairment associated with schizophrenia and the impact this has on both the patient and their loved ones.
THE COVID-19 PANDEMIC: IMPLICATIONS FOR PHYSICAL AND MENTAL HEALTH OF PEOPLE LIVING WITH SCHIZOPHRENIA
The symposium provided an update on the impact of COVID-19 on health status, treatment management, and access to care for people with schizophrenia.